**Supplemental tables**

**Table 1: Summary of mother- infant attrition and retention for the MIR4Health cohort at six months postpartum**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | N | Mother/infant died | Lost to follow –up | | Total attrition | Total retained\* |
|  |  |  | (Pregnancy loss) | (Unknown) |  |  |
|  | A | B | C | D | E=B+C+D | F=A-E |
| Total | 340 | 10 (2.9%) | 29 (8.5%) | 41(12.1%) | 80 (23·5%) | 260 (76·5%) |
| Intervention | 170 | 5(2.9%) | 12 (7.1%) | 15 (8.8%) | 32 (18.8%) | 138 (81.2%) |
| SOC | 170 | 5(2.9%) | 17 (10.0%) | 26 (15.3%) | 48 (28.2%) | 122 (71.8%) |
| A-number of subjects, B-maternal or infant death, C-pregnancy loss, D-mother or infant lost to follow-up, E- attrition, F- mother -infant pair retained at 6 months  \*Total retained includes verified transfers out; 8 in the intervention arm and 10 in the SOC arm, total 18 | | | | | | |

**Table 2: Factors associated with attrition of mother-infant pairs at six months postpartum**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Crude RR | 95% CI | Adjusted RR\* | 95% CI |
| Maternal age group |  |  |  |  |
| 16-24 years | 1 | Reference | 1 | Reference |
| 25-29 years | 0.70 | (0.39-1.23) | 0.78 | (0.44-1.39) |
| >30 years | 0.62 | (0.31-1.26) | 0.88 | (0.39-1.99) |
| Gestational age |  |  |  |  |
| <28 weeks | 1 | Reference | 1 | Reference |
| >=28 weeks | 0.85 | (0.56-1.29) | 0.78 | (0.47-1.30) |
| WHO stage |  |  |  |  |
| I/II | 1 | Reference | 1 | Reference |
| III | 0.91 | (0.34-2.43) | 0.88 | (0.34-2.25) |
| Marital status |  |  |  |  |
| No | 1 | Reference | 1 | Reference |
| Yes | 0.69 | (0.46-1.03) | 0.91 | (0.38-2.20) |
| Partner disclosure at study visit 1 |  |  |  |  |
| No | 1 | Reference | 1 | Reference |
| Yes | 0.63 | (0.41-0.97) | 0.69 | (0.44-1.07) |
| No partner | 1.37 | (0.68-2.79) | 1.34 | (0·47-3.82) |
| Antiretroviral regimen\*\* |  |  |  |  |
| New positive on AZT | 1 | Reference | 1 | Reference |
| Known positive on AZT | 0.37 | (0.13-1.05) | 0.41 | (0.14-1.21) |
| New positive on ART | 1.59 | (0.94-2.69) | 1·53 | (0.99-2.36) |
| Known positive on ART | 0.58 | (0.32-1.06) | 0.68 | (0.35-1.34) |
| No ARVs | 0.75 | (0.42-1.35) | 0.88 | (0.50-1.54) |
| \* Adjusted for study arm and all the other variables in the table, accounting for within-site correlation.  \*\* Antiretroviral regimen at study visit 2  RR-risk ratio, AZT-zidovudine, ART-antiretroviral treatment, ARVs-antiretroviral drugs | | | | |

**Table 3: Maternal viral suppression (<1000 copies/µl) and (< 40 copies/µl) at six months postpartum amongst women by study arm\***

|  |  |  |  |
| --- | --- | --- | --- |
|  | Intervention  (n=130) | SOC  (n=112) | Total  (n=242) |
|  | N (%) | N (%) | N (%) |
| Number (%) of women with VL test at 6 months | 122 (93.8) | 109 (97.3) | 231 (95.4) |
| Number (%) of women with VL <1000 copies/µl | 99/122 (81.2) | 83/109 (76.2) | 182/231 (78.8) |
| Number (%) of women on ART with VL <1000 copies/µl | 97/116 (83.6) | 79/100 (79.0) | 176/216(81.5) |
| <3 months on ART | 13/14 (92.9) | 10/15 (66.7) | 23/29 (79.3) |
| 3-6 months on ART | 30/35 (85.7) | 18/22 (81.8) | 48/57 (84.2) |
| 6-9 months on ART | 23/26 (88.5) | 17/20 (85.0) | 40/46 (87.0) |
| > 9 months on ART | 19/23 (82.6) | 34/43 (79.1) | 65/84 (77.4) |

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
| Number (%) of women with VL < 40 copies/µl | 83/122 (68.0) | 67/109 (61.5) | 150/231 (64.9) |
| Number (%) of women on ART with VL <40 copies/µl | 82/116 (70.7) | 67/100 (67.0) | 149/216 (69.0) |
| <3 months | 8/14 (57.1) | 6/15 (40.0) | 14/29 (48.3) |
| 3-6 months on ART | 26/35 (74.3) | 17/22 (77.3) | 43/57 (75.4) |
| 6-9 months on ART | 19/26 (73.1) | 15/20 (75.0) | 34/46 (73.9) |
| > 9 months on ART | 29/41 (70.7) | 29/43 (67.4) | 58/84 (69.1) |

|  |
| --- |
| Data are number (%), SOC- standard of care, VL- viral load, ART-antiretroviral therapy  \*All p values not significant |

**Table 4: Outcome for infants determined to be HIV-infected (n=9)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Study arm | Maternal regimen | Maternal VL at delivery | Age at diagnosis (weeks) | Age at enrollment (weeks) | Age at ART initiation (weeks) | Infant  regimen | Outcome at 6 months |
| 1 | Intervention | AZT | 19308 | 7 | N/A | N/A | N/A | Infant died |
| 2 | Intervention | AZT | 48820 | 7 | 19 | 19 | ABC/3TC/LPV/r | In care |
| 3 | SOC | Unknown | \* | 7 | 16 | 16 | ABC/3TC/LPV/r | In care |
| 4 | SOC | TDF/3TC/NVP | 141282 | 6 | 14 | 14 | AZT/3TC/LPV/r | In care |
| 5 | SOC | AZT/3TC/NVP | 4640 | 6 | 15 | 15 | ABC/3TC/LPV/r | In care |
| 6 | SOC | TDF/3TC/NVP | \* | 9 | 13 | 13 | ABC/3TC/NVP | In care |
| 7 | Intervention | AZT/3TC/NVP | 16752 | 29 | 29 | 31 | ABC/3TC/LPV/r | In care |
| 8 | SOC | AZT/3TC/NVP | 135548 | 26 | 33 | 33 | ABC/3TC/LPV/r | Lost to follow-up |
| 9 | SOC | TDF/3TC/NVP | 18358 | 26 | N/A | N/A | N/A | Infant died |
| ART- antiretroviral therapy, AZT- zidovudine, TDF- tenofovir, NVP-nevirapine, 3TC- lamivudine, ABC-abacavir, LPV/r- lopinavir/ritonavir, VL- viral load, N/A- not applicable  \* maternal viral load not done | | | | | | | | |